ACRO Biomedical Co., Ltd. (TPEX:6748)
Taiwan · Delayed Price · Currency is TWD 84.20
+2.50 (3.06%)
Aug 12, 2025, 1:59 PM CST
ACRO Biomedical Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2019 |
Net Income | -62.09 | -41.42 | -60.88 | -50.78 | -50.02 | Upgrade |
Depreciation & Amortization | 11.78 | 9.71 | 9.21 | 9.51 | 12.54 | Upgrade |
Other Amortization | 1.7 | 1.27 | - | - | - | Upgrade |
Loss (Gain) From Sale of Assets | 0.15 | - | - | - | - | Upgrade |
Loss (Gain) From Sale of Investments | 1.33 | -2.77 | -0.5 | -1.81 | - | Upgrade |
Stock-Based Compensation | 1.39 | - | 0.74 | 1.39 | 3.65 | Upgrade |
Provision & Write-off of Bad Debts | -1.85 | 3.55 | - | 0 | - | Upgrade |
Other Operating Activities | 0.35 | -20.46 | 4 | 0.53 | 0.22 | Upgrade |
Change in Accounts Receivable | -2.56 | 2.32 | -5.01 | -0.46 | -2.35 | Upgrade |
Change in Inventory | -1.72 | 2.9 | -1.96 | -1.69 | 1.6 | Upgrade |
Change in Accounts Payable | 0.36 | 0.09 | 0.24 | -0.13 | -0.13 | Upgrade |
Change in Unearned Revenue | 2.31 | 0.12 | -0.23 | -2.86 | 2.7 | Upgrade |
Change in Other Net Operating Assets | 5.47 | -3.58 | 7.68 | -1.52 | 0.46 | Upgrade |
Operating Cash Flow | -43.38 | -48.27 | -46.71 | -47.83 | -31.33 | Upgrade |
Capital Expenditures | -30.55 | -21 | -2.74 | -0.37 | -2.12 | Upgrade |
Sale of Property, Plant & Equipment | 0.02 | - | - | - | - | Upgrade |
Sale (Purchase) of Intangibles | -0.08 | -1.46 | -1.7 | -2.93 | -1.71 | Upgrade |
Investment in Securities | -272.13 | -10.6 | -4.1 | 40.21 | -71.12 | Upgrade |
Other Investing Activities | -1.92 | -0.54 | -0.45 | -0.05 | 0.26 | Upgrade |
Investing Cash Flow | -304.67 | -33.59 | -8.99 | 36.86 | -74.69 | Upgrade |
Long-Term Debt Repaid | -5.25 | -4.72 | -3.45 | -3.42 | -3.12 | Upgrade |
Net Debt Issued (Repaid) | -5.25 | -4.72 | -3.45 | -3.42 | -3.12 | Upgrade |
Issuance of Common Stock | - | 350 | 307.85 | - | 100 | Upgrade |
Financing Cash Flow | -5.25 | 345.28 | 304.4 | -3.42 | 96.88 | Upgrade |
Foreign Exchange Rate Adjustments | 0.89 | -1.1 | 0.88 | 1 | -0.67 | Upgrade |
Net Cash Flow | -352.41 | 262.31 | 249.58 | -13.4 | -9.8 | Upgrade |
Free Cash Flow | -73.93 | -69.27 | -49.45 | -48.2 | -33.45 | Upgrade |
Free Cash Flow Margin | -167.13% | -135.66% | -178.94% | -220.80% | -185.50% | Upgrade |
Free Cash Flow Per Share | -1.21 | -1.31 | -1.05 | -1.36 | -1.10 | Upgrade |
Cash Interest Paid | 0.29 | 0.26 | 0.1 | 0.09 | 0.1 | Upgrade |
Cash Income Tax Paid | 0.27 | 0.17 | 0.06 | - | - | Upgrade |
Levered Free Cash Flow | -54.55 | -34.55 | -29.07 | -32.07 | -20.42 | Upgrade |
Unlevered Free Cash Flow | -54.37 | -34.39 | -29 | -32.01 | -20.35 | Upgrade |
Change in Working Capital | 3.86 | 1.86 | 0.72 | -6.66 | 2.29 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.